Loading resource…

Suchira Gallage, Olivier Govaere, Quentin M. Anstee, Gerald I. Shulman, Frank Tacke, Mathias Heikenwalder
Metabolic dysfunction-associated steatotic liver disease (MASLD), including its progressive form metabolic dysfunction-associated steatohepatitis (MASH), is recognized as a multi-organ disease and the most prevalent chronic liver disease worldwide. The document outlines key pathogenic processes such as insulin resistance, genetic factors, and immune-mediated inflammation that contribute to the disease's progression. It also discusses emerging therapeutic strategies targeting metabolic pathways to improve patient outcomes. The insights provided are crucial for understanding the disease's impact on liver health and potential treatment options.
Sign in to open
Answers use this document only.
Your first question is free.
Resources from the same specialty and type. Curated links will replace these when added.
Documents that extend or complement this resource.

Hepatitis E Virus, Second Edition (Springer, 2023)
Same clinical topic · Hepatology

AUTOIMMUNE HEPATITIS
Same clinical topic · Hepatology

CIRRHOSIS, PORTAL HYPERTENSION AND HEPATOCELLULAR CARCINOMA: A STAGE-BASED APPROACH
Same clinical topic · Hepatology

NEW APPROACHES TO CHRONIC HEPATITIS B
Same clinical topic · Hepatology

CURRENT THERAPEUTIC LANDSCAPE AND FUTURE TREATMENT PERSPECTIVES OF MASH
Same clinical topic · Hepatology

RANDOMIZED, CONTROLLED CLINICAL TRIAL OF THE DIALIVE LIVER DIALYSIS DEVICE VERSUS STANDARD OF CARE IN PATIENTS WITH ACUTE ON-CHRONIC LIVER FAILURE
Same clinical topic · Hepatology

Intravenous albumin after outpatient paracentesis reduces the risk of AKI hospitalization: A national cohort study
Same clinical topic · Hepatology

LIVER TRANSPLANTATION FOR PATIENTS WITH SEVERE ACUTE ON CHRONIC LIVER FAILURE: IT IS TIME TO CHANGE PARADIGMS
Same clinical topic · Hepatology

HEPATITIS B
Same clinical topic · Hepatology